NSAID s

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Loading Image

Finding Sources

Searching PubMed

NSAIDs cardiovascular risk gastrointestinal safety

I now have comprehensive information to write a thorough answer on NSAIDs. Let me compile everything.

NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)

Overview

NSAIDs are one of the most widely prescribed drug classes worldwide, used for their analgesic, anti-inflammatory, and antipyretic effects. They form Step 1/2 of multimodal analgesic regimens and are used in pain, fever, inflammation, and numerous chronic conditions.

Mechanism of Action

NSAIDs work by inhibiting cyclooxygenase (COX) enzymes, which convert arachidonic acid (released from membrane phospholipids by phospholipases) into PGH2 - the precursor of all prostanoids (prostaglandins, prostacyclins, thromboxanes).

Arachidonic acid - COX pathway showing COX-1 and COX-2 leading to prostanoid products

The figure above shows how both COX-1 and COX-2 convert arachidonic acid to PGH2, which is then converted by tissue-specific isomerases to TXA2, PGI2 (prostacyclin), and PGE2.

There are two main COX isoforms:

Feature	COX-1	COX-2
Expression	Constitutive (always present)	Inducible (upregulated by inflammation, cytokines)
Location	Platelets, gastric mucosa, kidney, endothelium	Sites of inflammation, kidney, brain, endothelium
Products	TXA2 (platelet aggregation), PGI2, PGE2 (gastric protection)	PGE2 (inflammation, pain, fever), PGI2
Role	Housekeeping functions	Inflammation, pain, fever

By inhibiting COX, NSAIDs block:

Prostaglandin synthesis → less pain sensitization and inflammation
Thromboxane A2 (via COX-1) → reduced platelet aggregation
Prostacyclin (PGI2) (via COX-2) → vasodilation lost → potential pro-thrombotic state with selective COX-2 inhibitors

Classification

1. Non-selective COX-1 + COX-2 Inhibitors (tNSAIDs)

These inhibit both isoforms to varying degrees:

Propionic acids: Ibuprofen, Naproxen, Ketoprofen, Flurbiprofen
Acetic acids: Indomethacin, Diclofenac, Ketorolac, Sulindac, Etodolac
Oxicams: Piroxicam, Meloxicam (mild COX-2 preference)
Fenamates: Mefenamic acid
Pyrazolones: Phenylbutazone (largely withdrawn)
Salicylates: Aspirin (special - see below)

2. Selective COX-2 Inhibitors (Coxibs)

Celecoxib, Etoricoxib, Parecoxib (parenteral)
Former members (withdrawn due to CV risk): Rofecoxib (Vioxx), Valdecoxib, Lumiracoxib

3. Aspirin - Unique NSAID

Aspirin irreversibly acetylates a serine residue in the COX active site, permanently inactivating both COX-1 and COX-2. Because platelets lack a nucleus (cannot synthesize new enzyme), the antiplatelet effect lasts for the entire platelet lifespan (7-10 days). All other NSAIDs are reversible inhibitors. - Quick Compendium of Clinical Pathology, 5th ed.

COX-2 Selectivity Spectrum

The plot below shows the COX-2 selectivity of various drugs based on their IC50 ratios. Drugs to the right of the diagonal line have greater COX-2 than COX-1 selectivity:

COX-1 vs COX-2 IC50 scatter plot - selectivity of various NSAIDs

Key insight: Indomethacin is strongly COX-1 preferring; Diclofenac shows marked COX-2 preference despite being a "non-selective" NSAID; Celecoxib, Rofecoxib, Etoricoxib are the true coxibs with strong COX-2 selectivity.

Pharmacological Effects

Effect	Mechanism
Analgesia	Block PGE2/PGI2 sensitization of nociceptors; also central action at spinal cord
Anti-inflammation	Reduce PGE2 and PGI2 at inflammatory sites; decreased vasodilation, edema
Antipyresis	Block PGE2 synthesis in hypothalamus (resets the thermostat)
Antiplatelet	COX-1 inhibition reduces TXA2-driven platelet aggregation
Uricosuric	Some (e.g., sulindac) have mild uricosuric effects

Clinical Uses

Acute pain: Post-operative, dental, musculoskeletal, headache
Chronic inflammation: Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriatic arthritis
Acute gout attack: High-dose naproxen or indomethacin
Dysmenorrhea: First-line (ibuprofen, naproxen)
Fever: Second line after paracetamol in adults
Pericarditis: Aspirin or ibuprofen
Patent ductus arteriosus: Indomethacin IV (closes PDA in neonates)
Tocolysis: Indomethacin (inhibits uterine prostaglandin synthesis)
Cardiovascular prophylaxis: Low-dose aspirin (antiplatelet)
Actinic keratoses: Topical diclofenac 3% gel

Adverse Effects

Gastrointestinal (most common)

Mucosal damage from COX-1 inhibition: loss of protective PGE2/PGI2 → reduced mucus, bicarbonate, blood flow
Ranges from dyspepsia to gastric/duodenal ulcers and upper GI bleeding
COX-2-selective inhibitors significantly reduce GI risk
Management: Add a proton pump inhibitor (PPI) for high-risk patients; consider misoprostol
A 2026 meta-analysis (PMID: 40915652) confirmed all NSAIDs increase GI bleeding risk

Cardiovascular

COX-2 inhibition reduces PGI2 (vasodilatory/anti-thrombotic) without reducing TXA2 → net prothrombotic state
Risk of myocardial infarction and stroke, especially with selective COX-2 inhibitors
Even ibuprofen and naproxen carry some CV risk at high doses
Coxibs are contraindicated in perioperative CABG patients
Reduced renal PGI2/PGE2 → sodium/water retention → elevated blood pressure regardless of antihypertensive being taken - Rheumatology 2-Volume Set (Elsevier, 2022)

Renal

Prostaglandins dilate the afferent arteriole to maintain GFR, especially in states of reduced perfusion (heart failure, dehydration, cirrhosis)
NSAID use → afferent arteriole constriction → decreased GFR → acute kidney injury
Chronic use: analgesic nephropathy, interstitial nephritis, papillary necrosis
Contraindicated in acute/chronic renal failure

Hematological

Platelet dysfunction → prolonged bleeding time (all NSAIDs); irreversible with aspirin
Risk of perioperative bleeding (avoid pre-surgery unless specifically indicated)
NSAIDs displace warfarin from plasma proteins AND impair platelet function → amplify anticoagulation risk

Respiratory

Aspirin-exacerbated respiratory disease (AERD): In ~10% of asthmatics, NSAIDs divert arachidonic acid to the 5-LOX pathway → leukotrienes → bronchoconstriction
Can precipitate life-threatening asthma attacks
Aspirin desensitization is a treatment option

Hepatic

Rare hepatotoxicity (diclofenac has highest rate among NSAIDs)
Avoid in severe hepatic impairment

Obstetric

Contraindicated after 30 weeks gestation: Cause premature closure of the ductus arteriosus and oligohydramnios (reduced fetal renal blood flow)
Indomethacin is used as a tocolytic before 32 weeks with caution

Drug Interactions

Drug Affected	NSAID	Effect
Warfarin	All NSAIDs	Protein binding displacement + platelet inhibition → increased bleeding risk
Lithium	All NSAIDs	Inhibit renal excretion → lithium toxicity
Antihypertensives	All NSAIDs	Blunt antihypertensive effect (sodium retention, vasoconstriction)
Sulfonylureas	Phenylbutazone, azapropazone	Inhibit metabolism → prolonged hypoglycemia
Phenytoin	Phenylbutazone	Inhibit metabolism → phenytoin toxicity
ACE inhibitors	All NSAIDs	Reduce renal blood flow → hyperkalemia and AKI
Antiplatelet drugs	Non-selective NSAIDs (ibuprofen, naproxen)	Compete for COX-1 binding site → blunt aspirin's antiplatelet effect

Source: Rheumatology, 2-Volume Set (Elsevier, 2022)

Contraindications

Contraindication	Reason
Active peptic ulcer disease	Worsen GI mucosal damage
Acute/chronic renal failure	Loss of prostaglandin-dependent renal perfusion
Severe hepatic impairment	Impaired metabolism, hepatotoxicity risk
Asthma (aspirin-sensitive)	Precipitate bronchospasm via 5-LOX shunting
Pregnancy (>30 weeks)	Premature ductus arteriosus closure, oligohydramnios
Perioperative CABG	Thrombotic CV events (especially coxibs)
Platelet dysfunction / active GI bleed	Worsened hemostasis
Hypersensitivity	Cross-reactivity between NSAIDs

Key Individual Agents

Drug	Notes
Aspirin	Irreversible COX-1/2 inhibitor; low dose = antiplatelet; high dose = anti-inflammatory
Ibuprofen	Most commonly used OTC; moderate COX-1 preference; avoid with aspirin
Naproxen	Longer half-life (twice daily); may have lowest CV risk among tNSAIDs
Indomethacin	Most potent; used for gout, pericarditis, PDA closure; high GI/CNS toxicity
Diclofenac	Despite being non-selective, shows marked COX-2 preference in vitro; highest hepatotoxicity among NSAIDs
Ketorolac	Parenteral/IM for acute pain; limited to 5 days due to GI toxicity
Celecoxib	Selective COX-2; lower GI risk; still carries CV and renal risks
Etoricoxib	Highly selective COX-2; not available in all countries
Meloxicam	Mild COX-2 preference; lower GI risk than indomethacin

GI Protection Strategies

For patients requiring NSAIDs who are at high GI risk (age >65, prior ulcer/bleed, concomitant steroids, anticoagulants):

Prefer a selective COX-2 inhibitor (celecoxib)
Add a PPI (omeprazole, lansoprazole)
Add misoprostol (PGE1 analogue) - less used due to GI side effects of misoprostol itself
Use the lowest effective dose for the shortest duration

Sources: Fischer's Mastery of Surgery 8e; Rheumatology 2-Volume Set (Elsevier 2022); Bailey & Love's Short Practice of Surgery 28e; Ganong's Review of Medical Physiology 26e; Quick Compendium of Clinical Pathology 5e; Goldman-Cecil Medicine

Recent evidence note: A 2026 systematic review and meta-analysis (PMID: 40915652) confirmed that all NSAIDs increase GI bleeding risk, reinforcing the need for gastroprotection in high-risk patients. A 2025 systematic review on celecoxib safety (PMID: 40911151) supports celecoxib's improved GI profile, though cardiovascular and renal monitoring remains necessary.

This is a shared conversation. Sign in to Orris to start your own chat.